Ovarian cancer survival in sub-Saharan Africa by human development index and histological subtypes: A population-based registry study
- PMID: 38339849
- DOI: 10.1002/ijc.34877
Ovarian cancer survival in sub-Saharan Africa by human development index and histological subtypes: A population-based registry study
Abstract
Ovarian cancer (OC) is the fourth most common cancer of women in sub-Saharan Africa (SSA), although few data have been published on population-level survival. We estimate ovarian cancer survival in SSA by human development index and histological subtype, using data from seven population-based cancer registries in six countries: Kenya (Nairobi and Eldoret), Mauritius, Uganda (Kampala), Cote d'Ivoire (Abidjan), Ethiopia (Addis Ababa) and South Africa (Eastern Cape). A total of 644 cases diagnosed during 2008-2014 were included, with 77% being of epithelial subtypes (range 47% [Abidjan]-80% [Mauritius]). The overall observed survival in the study cohort was 73.4% (95% CI: 69.8, 77.0) at 1 year, 54.4% (95% CI: 50.4, 58.7) at 3 years and 45.0% (95% CI: 41.0, 49.4) at 5 years. Relative survival at Year 1 ranged from 44.4% in Kampala to 86.3% in Mauritius, with a mean for the seven series of 67.4%. Relative survival was highest in Mauritius at 72.2% and lowest in Kampala, Uganda at 19.5%, with a mean of 47.8%. There was no difference in survival by age at diagnosis. Patients from high and medium HDI countries had significantly better survival than those from low HDI countries. Women with cancers of epithelial cell origin had much lower survival compared to women with other histological subtypes (p = .02). Adjusted for the young age of the African patients with ovarian cancer (44% aged <50) survival is much lower than in USA or Europe, and underlines the need for improvements in the access to diagnosis and treatment of OC in SSA.
Keywords: HDI; epithelial; ovarian cancer; sub‐Saharan Africa; survival.
© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Similar articles
-
Trends in the incidence of ovarian cancer in sub-Saharan Africa.Int J Cancer. 2023 Apr 1;152(7):1328-1336. doi: 10.1002/ijc.34335. Epub 2022 Nov 7. Int J Cancer. 2023. PMID: 36274630
-
Cancer survival in sub-Saharan Africa (SURVCAN-3): a population-based study.Lancet Glob Health. 2024 Jun;12(6):e947-e959. doi: 10.1016/S2214-109X(24)00130-X. Lancet Glob Health. 2024. PMID: 38762297 Free PMC article.
-
Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study.Int J Cancer. 2020 Dec 1;147(11):3037-3048. doi: 10.1002/ijc.33120. Epub 2020 Jun 19. Int J Cancer. 2020. PMID: 32449157
-
Revisiting sub-Saharan African countries' drug problems: health, social, economic costs, and drug control policy.Subst Use Misuse. 2002 Feb;37(3):265-90. doi: 10.1081/ja-120002479. Subst Use Misuse. 2002. PMID: 11913904 Review.
-
Survival Patterns Among Patients With Breast Cancer in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.JAMA Netw Open. 2024 May 1;7(5):e2410260. doi: 10.1001/jamanetworkopen.2024.10260. JAMA Netw Open. 2024. PMID: 38743426 Free PMC article.
References
REFERENCES
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249.
-
- Cabasag CJ, Fagan PJ, Ferlay J, et al. Ovarian cancer today and tomorrow: a global assessment by world region and human development index using GLOBOCAN 2020. Int J Cancer. 2022;151(9):1535‐1541.
-
- Ngwa W, Addai BW, Adewole I, et al. Cancer in sub‐Saharan Africa: a lancet oncology commission. Lancet Oncol. 2022;23(6):e251‐e312.
-
- Bray F, Parkin DM. Cancer in sub‐Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs. Lancet Oncol. 2022;23(6):719‐728.
-
- Soerjomataram I, Cabasag C, Bardot A, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN‐3): a population‐based benchmarking study in 32 countries. Lancet Oncol. 2023;24(1):22‐32.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials